GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Resources Sanjiu Medical & Pharmaceutical Co Ltd (SZSE:000999) » Definitions » ROC %

China Resourcesnjiu Medical & Pharmaceutical Co (SZSE:000999) ROC % : 26.07% (As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is China Resourcesnjiu Medical & Pharmaceutical Co ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. China Resourcesnjiu Medical & Pharmaceutical Co's annualized return on capital (ROC %) for the quarter that ended in Mar. 2024 was 26.07%.

As of today (2024-04-27), China Resourcesnjiu Medical & Pharmaceutical Co's WACC % is 7.73%. China Resourcesnjiu Medical & Pharmaceutical Co's ROC % is 15.82% (calculated using TTM income statement data). China Resourcesnjiu Medical & Pharmaceutical Co generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


China Resourcesnjiu Medical & Pharmaceutical Co ROC % Historical Data

The historical data trend for China Resourcesnjiu Medical & Pharmaceutical Co's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Resourcesnjiu Medical & Pharmaceutical Co ROC % Chart

China Resourcesnjiu Medical & Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.45 13.90 17.25 16.54 17.26

China Resourcesnjiu Medical & Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.57 14.80 11.75 11.07 26.07

China Resourcesnjiu Medical & Pharmaceutical Co ROC % Calculation

China Resourcesnjiu Medical & Pharmaceutical Co's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=3990.559 * ( 1 - 15.47% )/( (16911.683 + 22180.46)/ 2 )
=3373.2195227/19546.0715
=17.26 %

where

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=27122.782 - 7061.39 - ( 3149.709 - max(0, 8672.699 - 11988.49+3149.709))
=16911.683

Invested Capital(A: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=40148.456 - 9741.209 - ( 8226.787 - max(0, 12946.975 - 22522.003+8226.787))
=22180.46

China Resourcesnjiu Medical & Pharmaceutical Co's annualized Return on Capital (ROC %) for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=7321.268 * ( 1 - 19.41% )/( (22180.46 + 23079.683)/ 2 )
=5900.2098812/22630.0715
=26.07 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=40148.456 - 9741.209 - ( 8226.787 - max(0, 12946.975 - 22522.003+8226.787))
=22180.46

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=41247.674 - 9338.09 - ( 8829.901 - max(0, 12604.45 - 23687.907+8829.901))
=23079.683

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


China Resourcesnjiu Medical & Pharmaceutical Co  (SZSE:000999) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, China Resourcesnjiu Medical & Pharmaceutical Co's WACC % is 7.73%. China Resourcesnjiu Medical & Pharmaceutical Co's ROC % is 15.82% (calculated using TTM income statement data). China Resourcesnjiu Medical & Pharmaceutical Co generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


China Resourcesnjiu Medical & Pharmaceutical Co ROC % Related Terms

Thank you for viewing the detailed overview of China Resourcesnjiu Medical & Pharmaceutical Co's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


China Resourcesnjiu Medical & Pharmaceutical Co (SZSE:000999) Business Description

Traded in Other Exchanges
N/A
Address
High-Tech Park, Lake Street Mission Hills, Longhua District, Shenzhen, CHN, 518110
China Resources Sanjiu Medical & Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in the research and development, production and sale of pharmaceutical products, healthcare products, and medical appliances under the brand name 999, which includes OTC, antibiotic and raw material drug. The other brands under which the company offers its products are Lee King, Shunfeng, and Tianhe. The company's core business is located in OTC and Chinese medicine prescription drugs, OTC core products in the cold, gastrointestinal, skin, pediatric, cough and orthopedic drugs occupy a higher market share; prescription drug products in traditional Chinese medicine formula granules, cardiovascular and cerebrovascular, anti-tumor in the field of anti-infection and other areas.

China Resourcesnjiu Medical & Pharmaceutical Co (SZSE:000999) Headlines

No Headlines